Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
CIRM leaders outline reprioritized strategic plan, DEI measures, and patient-assistance pilot
Summary
CIRM President Jonathan Thomas told the oversight committee that the agency has reprioritized deployment of remaining Prop 14 funds around six strategic goals, is piloting a patient-assistance program from licensing revenues, and embeds DEI criteria in grant review and clinical trial patient recruitment.
Jonathan Thomas, president and CEO of the California Institute for Regenerative Medicine (CIRM), presented a comprehensive update to the Citizens Financial Accountability Oversight Committee on Dec. 18, detailing a reprioritized Strategic Allocation Framework (SAF) for the agencythat guides how roughly $3.8 billion in remaining Prop 14 funds will be deployed.
Thomas said the SAF is data-driven and lists six priority areas: increased support for basic research, tools and enabling technologies (for example gene editing), advancing a set number of rare-disease programs to biologics license application (BLA) readiness, funding 1520to2020 later-stage programs for more prevalent conditions, improving…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
